BR112015024272A2 - novos derivados de piridina - Google Patents
novos derivados de piridinaInfo
- Publication number
- BR112015024272A2 BR112015024272A2 BR112015024272A BR112015024272A BR112015024272A2 BR 112015024272 A2 BR112015024272 A2 BR 112015024272A2 BR 112015024272 A BR112015024272 A BR 112015024272A BR 112015024272 A BR112015024272 A BR 112015024272A BR 112015024272 A2 BR112015024272 A2 BR 112015024272A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyridine derivatives
- new pyridine
- new
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
1/1 resumo novos derivados de piridina a invenção refere-se a um composto da fórmula (i) 3 r r2r41 r na (i) em que a e r1 a r4 são tais como se encontram definidos na descrição e nas reivindicações. o composto da fórmula (i) pode ser usado na forma de um medicamento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13161176 | 2013-03-26 | ||
| PCT/EP2014/055797 WO2014154612A1 (en) | 2013-03-26 | 2014-03-24 | Novel pyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015024272A2 true BR112015024272A2 (pt) | 2017-07-18 |
Family
ID=47913322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015024272A BR112015024272A2 (pt) | 2013-03-26 | 2014-03-24 | novos derivados de piridina |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US10308659B2 (pt) |
| EP (1) | EP2978755B1 (pt) |
| JP (1) | JP6500010B2 (pt) |
| KR (1) | KR20150135458A (pt) |
| CN (1) | CN105121436B (pt) |
| AR (1) | AR095721A1 (pt) |
| AU (1) | AU2014243190B2 (pt) |
| BR (1) | BR112015024272A2 (pt) |
| CA (1) | CA2899168A1 (pt) |
| CL (1) | CL2015002835A1 (pt) |
| CR (1) | CR20150440A (pt) |
| DK (1) | DK2978755T3 (pt) |
| EA (1) | EA027569B1 (pt) |
| ES (1) | ES2661737T3 (pt) |
| HK (1) | HK1211938A1 (pt) |
| HR (1) | HRP20180371T1 (pt) |
| HU (1) | HUE036934T2 (pt) |
| IL (1) | IL240496B (pt) |
| LT (1) | LT2978755T (pt) |
| MA (1) | MA38404B1 (pt) |
| MX (1) | MX365921B (pt) |
| MY (1) | MY174000A (pt) |
| NO (1) | NO2978755T3 (pt) |
| PE (1) | PE20151559A1 (pt) |
| PH (1) | PH12015501933A1 (pt) |
| PL (1) | PL2978755T3 (pt) |
| PT (1) | PT2978755T (pt) |
| RS (1) | RS56927B1 (pt) |
| SG (1) | SG11201507994QA (pt) |
| SI (1) | SI2978755T1 (pt) |
| TW (1) | TWI628174B (pt) |
| UA (1) | UA116239C2 (pt) |
| WO (1) | WO2014154612A1 (pt) |
| ZA (1) | ZA201505251B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9708341B2 (en) * | 2014-06-09 | 2017-07-18 | Sumitomo Chemical Company, Limited | Method for producing pyridine compound |
| CR20180298A (es) * | 2015-12-09 | 2018-07-18 | Hoffmann La Roche | Nuevos derivados de fenilo |
| PL3481201T3 (pl) * | 2016-07-07 | 2021-03-22 | Corteva Agriscience Llc | Sposoby wytwarzania 4-alkoksy-3-(acylo lub alkilo)oksypikolinamidów |
| TW202334101A (zh) * | 2017-04-06 | 2023-09-01 | 美商富曼西公司 | 殺真菌之噁二唑 |
| EP3642200B1 (en) | 2017-06-20 | 2023-05-03 | F. Hoffmann-La Roche AG | Pyridine derivatives |
| WO2019003956A1 (ja) * | 2017-06-27 | 2019-01-03 | 住友化学株式会社 | オキサジアゾール化合物及びその用途 |
| CN108774220B (zh) * | 2018-05-27 | 2019-04-23 | 西安培华学院 | 用于治疗心肌缺血的化合物及其应用 |
| CN112638430B (zh) | 2018-06-27 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 放射性标记的大麻素受体2配体 |
| WO2020002270A1 (en) | 2018-06-27 | 2020-01-02 | F. Hoffmann-La Roche Ag | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists |
| PE20210368A1 (es) | 2018-06-27 | 2021-02-26 | Eth Zuerich | Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2 |
| CN114195759B (zh) * | 2021-08-26 | 2023-10-20 | 上海零诺生物科技有限公司 | 一种2-甲基-5-（1-甲基吡咯烷-2-基）吡啶制备方法 |
| EP4419508A2 (en) * | 2021-10-22 | 2024-08-28 | Carmot Therapeutics, Inc. | Oxazole, oxadiazole, and indole derivatives for the inhibition of usp28 |
| CN115073366B (zh) * | 2022-06-08 | 2024-08-09 | 都创(重庆)医药科技有限公司 | 一种基于微通道技术快速制备3-氯吡啶-2-甲酸的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2479744A1 (en) * | 2002-03-28 | 2003-10-09 | Paul E. Finke | Substituted 2,3-diphenyl pyridines |
| JP5406716B2 (ja) * | 2006-08-07 | 2014-02-05 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | インドール化合物 |
| US20100227845A1 (en) * | 2007-10-18 | 2010-09-09 | Zhicai Wu | Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| UA111640C2 (uk) | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 |
| EP2870139B1 (en) | 2012-07-04 | 2016-06-15 | F.Hoffmann-La Roche Ag | Novel adamantyl derivatives as cannabinoid receptor 2 agonists |
| MX2015007155A (es) | 2012-12-07 | 2015-10-14 | Hoffmann La Roche | Nuevos derivados de piridina. |
| PE20151089A1 (es) | 2012-12-07 | 2015-08-06 | Hoffmann La Roche | Piridin-2-amidas utiles como agonistas de cb2 |
| MX2015007156A (es) | 2012-12-07 | 2015-10-14 | Hoffmann La Roche | Piridina-2-amidas utiles como agonistas receptores de canabinoides 2 (cb2). |
| IN2015DN03145A (pt) | 2012-12-07 | 2015-10-02 | Hoffmann La Roche | |
| PL2964646T3 (pl) | 2013-03-07 | 2017-09-29 | F.Hoffmann-La Roche Ag | Nowe pochodne pirazolu |
| PE20161370A1 (es) | 2014-04-04 | 2016-12-17 | Hoffmann La Roche | Nuevos derivados de piridina utiles como antagonistas de cb2 |
| AR099932A1 (es) | 2014-04-04 | 2016-08-31 | Hoffmann La Roche | Derivados de piridina |
-
2014
- 2014-03-24 BR BR112015024272A patent/BR112015024272A2/pt not_active Application Discontinuation
- 2014-03-24 EA EA201591567A patent/EA027569B1/ru not_active IP Right Cessation
- 2014-03-24 SI SI201430615T patent/SI2978755T1/en unknown
- 2014-03-24 RS RS20180226A patent/RS56927B1/sr unknown
- 2014-03-24 JP JP2016504604A patent/JP6500010B2/ja not_active Expired - Fee Related
- 2014-03-24 WO PCT/EP2014/055797 patent/WO2014154612A1/en active Application Filing
- 2014-03-24 PT PT147122873T patent/PT2978755T/pt unknown
- 2014-03-24 EP EP14712287.3A patent/EP2978755B1/en not_active Not-in-force
- 2014-03-24 SG SG11201507994QA patent/SG11201507994QA/en unknown
- 2014-03-24 KR KR1020157030611A patent/KR20150135458A/ko not_active Application Discontinuation
- 2014-03-24 MX MX2015013629A patent/MX365921B/es active IP Right Grant
- 2014-03-24 ES ES14712287.3T patent/ES2661737T3/es active Active
- 2014-03-24 MA MA38404A patent/MA38404B1/fr unknown
- 2014-03-24 PE PE2015002063A patent/PE20151559A1/es active IP Right Grant
- 2014-03-24 PL PL14712287T patent/PL2978755T3/pl unknown
- 2014-03-24 LT LTEP14712287.3T patent/LT2978755T/lt unknown
- 2014-03-24 DK DK14712287.3T patent/DK2978755T3/en active
- 2014-03-24 UA UAA201510076A patent/UA116239C2/uk unknown
- 2014-03-24 CN CN201480017405.4A patent/CN105121436B/zh not_active Expired - Fee Related
- 2014-03-24 AU AU2014243190A patent/AU2014243190B2/en not_active Ceased
- 2014-03-24 NO NO14712287A patent/NO2978755T3/no unknown
- 2014-03-24 MY MYPI2015703306A patent/MY174000A/en unknown
- 2014-03-24 HU HUE14712287A patent/HUE036934T2/hu unknown
- 2014-03-24 CA CA2899168A patent/CA2899168A1/en not_active Abandoned
- 2014-03-25 TW TW103111118A patent/TWI628174B/zh not_active IP Right Cessation
- 2014-03-25 AR ARP140101336A patent/AR095721A1/es unknown
-
2015
- 2015-07-21 ZA ZA2015/05251A patent/ZA201505251B/en unknown
- 2015-08-10 IL IL240496A patent/IL240496B/en active IP Right Grant
- 2015-08-25 CR CR20150440A patent/CR20150440A/es unknown
- 2015-09-02 PH PH12015501933A patent/PH12015501933A1/en unknown
- 2015-09-23 CL CL2015002835A patent/CL2015002835A1/es unknown
- 2015-09-28 US US14/868,305 patent/US10308659B2/en not_active Expired - Fee Related
- 2015-12-30 HK HK15112855.2A patent/HK1211938A1/xx not_active IP Right Cessation
-
2018
- 2018-03-01 HR HRP20180371TT patent/HRP20180371T1/hr unknown
-
2019
- 2019-04-24 US US16/393,794 patent/US20190248803A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015013124A2 (pt) | novos derivados de piridina | |
| BR112015024272A2 (pt) | novos derivados de piridina | |
| BR112013031463A2 (pt) | piridina-2-amidas úteis como agonistas de cb2 | |
| BR112015012919A2 (pt) | novos derivados de piridina | |
| BR112015020795A2 (pt) | derivados de pirazol novos | |
| BR112015009600A2 (pt) | piridina-2-amidas úteis como agonistas cb2 | |
| BR112015009603A2 (pt) | novos derivados de pirazina | |
| GT201400144A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| BR112015027396A2 (pt) | derivados de purina como agonistas do receptor de cb2 | |
| BR112018011562A2 (pt) | novos derivados de fenil | |
| BR112014010047A8 (pt) | novos derivados de pirazina | |
| BR112015027394A8 (pt) | derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2 | |
| BR112015023161A8 (pt) | derivados de piridin-4-ila | |
| BR112014016803A2 (pt) | amidas macrocíclicas como inibidoras de protease | |
| BR112014019220A8 (pt) | Novos derivados de pirrolidina | |
| BR112018075143A2 (pt) | derivados de [1,2,3] triazolo [4,5-d] pirimidina com afinidade para o receptor de canabonóide tipo 2 | |
| BR112015030824A2 (pt) | novos derivados de tetrazolona | |
| CO7200259A2 (es) | Nuevos derivados de piridina | |
| BR112015010469A2 (pt) | derivados de imidazopiridina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |